Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease As of January 31, 2022, 157 patients were treated (median age, 64 years [range, 20‐83]; median of three [range, 2-11] ...
CD20 × CD3 bispecific antibodies bind to both CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity, which triggers T cell-mediated killing of the targeted B cells. CD20 × ...
The review concludes that CD20-targeted chimeric antigen receptor (CAR) T-cell therapy is an option worth exploring, despite potential safety concerns that warrant more extensive research. CAR T-cell ...
Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to ...
National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide Seven days before the first ...
Anti-CD20 monoclonal antibodies are a class of therapeutic antibodies that target a specific protein called CD20 found on the surface of B cells, a type of white blood cell. These antibodies are ...
This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results